An E2F7/TSC1-based model for predicting the efficacy of sirolimus after liver transplantation for hepatocellular carcinoma beyond the Milan criteria-Reference-Cited by-同舟云学术

An E2F7/TSC1-based model for predicting the efficacy of sirolimus after liver transplantation for hepatocellular carcinoma beyond the Milan criteria

Published:2024-05-17 Issue:16 Volume:137 Page:1973-1975
ISSN:0366-6999
Container-title:Chinese Medical Journal
language:en
Short-container-title:

Author:

Zhang Lincheng¹,Zhou Wei¹,Zheng Shusen²³⁴,Ling Sunbin¹⁵,Xu Xiao¹⁴⁶

Affiliation:

1. Zhejiang University School of Medicine, Hangzhou, Zhejiang 310058, China

2. Shulan (Hangzhou) Hospital, Zhejiang Shuren University School of Medicine, Hangzhou, Zhejiang 310022, China

3. Department of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, China

4. National Center for Healthcare Quality Management in Liver Transplant, Hangzhou, Zhejiang 310003, China

5. Department of Hepatobiliary and Pancreatic Surgery, Hangzhou First People’s Hospital, Hangzhou, Zhejiang 310006, China

6. School of Clinical Medicine, Hangzhou Medical College, Hangzhou, Zhejiang 310014, China

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference5 articles.

1. Clinical practice guideline on liver transplantation for hepatocellular carcinoma in China (2021 edition);Chen;Chin Med J,2022

2. Sirolimus-based immunosuppression improves the prognosis of liver transplantation recipients with low TSC1/2 expression in hepatocellular carcinoma beyond the Milan criteria;Ye;Eur J Surg Oncol,2021

3. E2F7 promotes mammalian target of rapamycin inhibitor resistance in hepatocellular carcinoma after liver transplantation;Ling;Am J Transplant,2022

4. USP22 promotes hypoxia-induced hepatocellular carcinoma stemness by a HIF1α/USP22 positive feedback loop upon TP53 inactivation;Ling;Gut,2020

5. Drug development in the era of precision medicine;Dugger;Nat Rev Drug Discov,2018